litlas
Log inCreate account

Stephen B. Hanauer

Active 1986–2025

Also published as
STEPHEN B. HANAUER · Stephen B Hanauer
198
Papers
80,425
Citations
123
h-index
189
i10-index

Citations

Citations per year for Stephen B. Hanauer1987: 1 citations1988: 3 citations1989: 8 citations1990: 8 citations1991: 22 citations1992: 9 citations1993: 17 citations1994: 17 citations1995: 29 citations1996: 26 citations1997: 36 citations1998: 54 citations1999: 138 citations2000: 214 citations2001: 273 citations2002: 503 citations2003: 524 citations2004: 530 citations2005: 594 citations2006: 664 citations2007: 737 citations2008: 710 citations2009: 634 citations2010: 714 citations2011: 712 citations2012: 583 citations2013: 715 citations2014: 764 citations2015: 763 citations2016: 719 citations2017: 787 citations2018: 759 citations2019: 2,379 citations2020: 2,347 citations2021: 1,888 citations2022: 1,541 citations2023: 1,250 citations2024: 1,865 citations2025: 823 citations2026: 25 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,732 citing papers, 23.5% of this breakdownUnited Kingdom: 1,608 citing papers, 8% of this breakdownCanada: 1,353 citing papers, 6.7% of this breakdownItaly: 1,168 citing papers, 5.8% of this breakdownChina: 1,112 citing papers, 5.5% of this breakdownGermany: 1,110 citing papers, 5.5% of this breakdownFrance: 1,072 citing papers, 5.4% of this breakdownNetherlands: 754 citing papers, 3.8% of this breakdownBelgium: 703 citing papers, 3.5% of this breakdownJapan: 606 citing papers, 3% of this breakdownSpain: 589 citing papers, 2.9% of this breakdownAustralia: 520 citing papers, 2.6% of this breakdown
0%23.5%Other 23.8%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology58.6%
  • Medicine26.1%
  • Immunology and Microbiology9.7%
  • Neuroscience1.3%
  • Nursing1.1%
  • Agricultural and Biological Sciences1%
  • Other2.2%

Topics

  • Inflammatory Bowel Disease20.2%
  • Microscopic Colitis7%
  • Gut microbiota and health3.5%
  • Rheumatoid Arthritis Research and Therapies3.5%
  • Autoimmune and Inflammatory Disorders3.1%
  • Biosimilars and Bioanalytical Methods2.1%
  • Other60.6%

Coauthors

All papers

Open in search
  1. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

    Authors: Brian G. Feagan, Paul Rutgeerts, Bruce E. Sands, Stephen B. Hanauer, Jean‐Frédéric Colombel, William J. Sandborn, Gert Van Assche, Jeffrey Axler, Hyo Jong Kim, Silvio Danese, Irving H. Fox, Catherine Milch, Serap Sankoh, Tim Wyant, Jing Xu, Asit Parikh - New England Journal of Medicine 2013 cited by 2,852

  2. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

    Authors: Brian G. Feagan, William J. Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R. Friedman, Marion Blank, Jewel Johanns, Long-Long Gao, Miao Ye, Omoniyi J. Adedokun, Bruce E. Sands, Stephen B. Hanauer, Séverine Vermeire, Stephan R. Targan, Subrata Ghosh, Willem J. de Villiers, Jean–Frédéric Colombel, Zsolt Tulassay, Ursula Seidler, Bruce Salzberg, Pierre Desreumaux, Scott D. Lee, Edward V. Loftus, Levinus A. Dieleman, Seymour Katz, Paul Rutgeerts - New England Journal of Medicine 2016 cited by 1,806

  3. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

    Authors: William J. Sandborn, Brian G. Feagan, Paul Rutgeerts, Stephen B. Hanauer, Jean‐Frédéric Colombel, Bruce E. Sands, Milan Lukáš, Richard N. Fedorak, Scott Lee, Brian Bressler, Irving H. Fox, Maria Rosario, Serap Sankoh, Jing Xu, Kristin Stephens, Catherine Milch, Asit Parikh - New England Journal of Medicine 2013 cited by 2,687

  4. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

    Authors: Paul Rutgeerts, William J. Sandborn, Brian G. Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Suzanne Travers, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J.S. de Villiers, Daniel H. Present, Bruce E. Sands, Jean‐Frédéric Colombel - New England Journal of Medicine 2005 cited by 3,883

  5. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

    Authors: William J. Sandborn, Brian G. Feagan, Geert D’Haens, Douglas C. Wolf, Igor Jovanović, Stephen B. Hanauer, Subrata Ghosh, AnnKatrin Petersen, Steven Y. Hua, Ji Hwan Lee, Lorna Charles, Denesh K. Chitkara, Keith Usiskin, Jean–Frédéric Colombel, Loren Laine, Silvio Danese - New England Journal of Medicine 2021 cited by 532

  6. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

    Authors: Laurent Peyrin‐Biroulet, William J. Sandborn, Bruce E. Sands, Walter Reinisch, Willem A. Bemelman, Robert V. Bryant, Geert D’Haens, Iris Dotan, Marla C. Dubinsky, Brian G. Feagan, Gionata Fiorino, Richard B. Gearry, Suneeta Krishnareddy, Péter L. Lakatos, Edward V. Loftus, Philippe Marteau, Pia Munkholm, Travis B. Murdoch, Íngrid Ordás, Remo Panaccione, Robert H. Riddell, Joannie Ruel, David T. Rubin, Mark Samaan, Corey A. Siegel, Mark S. Silverberg, Jaap Stoker, S Schreiber, Simon Travis, Gert Van Assche, Silvio Danese, Julián Panés, Guillaume Bouguen, Sarah O’Donnell, Benjamin Pariente, Shawn Winer, Stephen B. Hanauer, J -F Colombel - The American Journal of Gastroenterology 2015 cited by 1,838

  7. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

    Authors: Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein, Lloyd Mayer, Stefan Schreiber, Jean‐Frédéric Colombel, Daniel Rachmilewitz, Douglas C. Wolf, Allan Olson, Weihang Bao, Paul Rutgeerts - The Lancet 2002 cited by 4,163

  8. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

    Authors: Bruce E. Sands, Peter M. Irving, Timothy Hoops, James Izanec, Long-Long Gao, Christopher Gasink, Andrew Greenspan, Matthieu Allez, Silvio Danese, Stephen B. Hanauer, Vipul Jairath, Tanja Kuehbacher, James D. Lewis, Edward V. Loftus, Emese Mihály, Remo Panaccione, Ellen Scherl, О. Б. Щукина, William J. Sandborn, Anita Afzali, Lilia Aitova, Xavier Aldeguer i Mante, Matthieu Allez, I Altorjay, Federico Argüelles‐Arias, Alessandro Armuzzi, Monika Augustyn, Mauro Bafutto, Jésus Barrio, Jakob Begun, Clint Behrend, Geert Bezemer, Guillaume Bonnaud, Marija Branković, Ik Jang Byung, Xavier Calvet, Karen A. Chachu, Júlio Maria Fonseca Chebli, Jae Hee Cheon, Halina Cichoż‐Lach, Larry Clark, Fraser Cummings, Kunal Dalal, Silvio Danese, Nanne K.H. de Boer, Maria de Lourdes Abreu Ferrari, Étienne Désilets, Predrag Dugalić, George Duvall, Olga Fedorishina, Rafał Filip, Cristina Flores, Ronald Fogel, James Fon, Michael Frankel, Keith Friedenberg, Walter Fries, Vassileva Galina, Piotr Gietka, Rishi Goel, Peter Hasselblatt, Hans Herfarth, László Herszényi, Pieter Hindryckx, Frank Hoentjen, Carmen Horjus Talabur Horje, Satish Iduru, Peter M. Irving, Robert J. Isfort, Vipul Jairath, Michael Jones, Dilara Kalimullina, Jeffry Katz, Manreet Kaur, Sunil K Khurana, Joo Sung Kim, Young‐Ho Kim, D Kleczkowski, Slavko Knezevic, Aaron Knoll, Louis Y Korman, Iskren Kotzev, Andrey Kulyapin, Kang‐Moon Lee, Desirée Leemreis, Jarosław Leszczyszyn, Jimmy K. Limdi, Jack J. Lissauer, Edward V. Loftus, Ewa Małecka‐Panas, John K. Marshall, Emese Mihály, Lukáš Milan, Giovanni Monteleone, Aleksandar Nagorni, Danuta Owczarek, Nichole Palekar, Remo Panaccione, Young Soo Park, Sang Hyoung Park and 43 more - The Lancet 2022 cited by 297

  9. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

    Authors: Yasunori Ogura, Denise K. Bonen, Naohiro Inohara, Dan L. Nicolae, Felicia F. Chen, Richard Ramos, Heidi Britton, Thomas Moran, Reda Karaliuskas, Richard H. Duerr, Jean–Paul Achkar, Steven R. Brant, Theodore M. Bayless, Barbara S. Kirschner, Stephen B. Hanauer, Gabriel Núñez, Judy H. Cho - Nature 2001 cited by 5,033

  10. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial

    Authors: Jean–Frédéric Colombel, William J. Sandborn, Paul Rutgeerts, Robert Enns, Stephen B. Hanauer, Remo Panaccione, Stefan Schreiber, Dan Byczkowski, Ju Li, Jeffrey D. Kent, Paul F. Pollack - Gastroenterology 2006 cited by 2,250

  11. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

    Authors: William J. Sandborn, Christopher Gasink, Long-Long Gao, Marion Blank, Jewel Johanns, Cynthia Guzzo, Bruce E. Sands, Stephen B. Hanauer, Stephan R. Targan, Paul Rutgeerts, Subrata Ghosh, Willem J.S. de Villiers, Remo Panaccione, Gordon R. Greenberg, Stefan Schreiber, Simon Lichtiger, Brian G. Feagan - New England Journal of Medicine 2012 cited by 1,128

  12. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

    Authors: Simon Travis, Dan Schnell, Piotr Krzeski, María T. Abreu, Douglas G. Altman, Jean–Frédéric Colombel, Brian G. Feagan, Stephen B. Hanauer, Marc Lémann, Gary R. Lichtenstein, Phillippe R Marteau, Walter Reinisch, Bruce E. Sands, Bruce Yacyshyn, Christian A. Bernhardt, Jean‐Yves Mary, William J. Sandborn - Gut 2011 cited by 626

  13. Neutrophil-induced genomic instability impedes resolution of inflammation and wound healing

    Authors: Veronika Butin‐Israeli, Triet M. Bui, Hannah L. Wiesolek, Lorraine Mascarenhas, Joseph J. Lee, Lindsey Catherine Mehl, Kaitlyn R. Knutson, Stephen A. Adam, Robert D. Goldman, Arthur Beyder, Lisa Wiesmüller, Stephen B. Hanauer, Ronen Sumagin - Journal of Clinical Investigation 2019 cited by 231

  14. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

    Authors: Stephan R. Targan, Stephen B. Hanauer, Sander J. H. van Deventer, Lloyd Mayer, Daniel H. Present, Tanja Braakman, Kimberly L. DeWoody, T Schaible, Paul Rutgeerts - New England Journal of Medicine 1997 cited by 3,160

  15. Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease

    Authors: Daniel H. Present, Paul Rutgeerts, Stephan Targan, Stephen B. Hanauer, Lloyd Mayer, R. A. van Hogezand, Daniel K. Podolsky, Bruce E. Sands, Tanja Braakman, Kimberly L. DeWoody, T Schaible, Sander J. H. van Deventer - New England Journal of Medicine 1999 cited by 2,747

  16. Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial

    Authors: Stephen B. Hanauer, William J. Sandborn, Paul Rutgeerts, Richard N. Fedorak, Milan Lukáš, Donald MacIntosh, Remo Panaccione, Douglas C. Wolf, Paul Pollack - Gastroenterology 2006 cited by 1,716

  17. Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

    Authors: Bruce E. Sands, Brian G. Feagan, Paul Rutgeerts, Jean‐Frédéric Colombel, William J. Sandborn, Richmond Sy, Geert D’Haens, Shomron Ben‐Horin, Jing Xu, Maria Rosario, Irving H. Fox, Asit Parikh, Catherine Milch, Stephen B. Hanauer - Gastroenterology 2014 cited by 705

  18. Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis

    Authors: Jean‐Frédéric Colombel, Paul Rutgeerts, Walter Reinisch, Dirk Eßer, Yanxin Wang, Yinghua Lang, Colleen Marano, Richard Strauß, B.J. Oddens, Brian G. Feagan, Stephen B. Hanauer, Gary R. Lichtenstein, Daniel H. Present, Bruce E. Sands, William J. Sandborn - Gastroenterology 2011 cited by 919

  19. Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity

    Authors: Simon Travis, Dan Schnell, Piotr Krzeski, María T. Abreu, Douglas G. Altman, Jean–Frédéric Colombel, Brian G. Feagan, Stephen B. Hanauer, Gary R. Lichtenstein, Philippe Marteau, Walter Reinisch, Bruce E. Sands, Bruce Yacyshyn, Patrick Schnell, Christian A. Bernhardt, Jean–Yves Mary, William J. Sandborn - Gastroenterology 2013 cited by 446

  20. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions

    Authors: Laurent Peyrin‐Biroulet, Julián Panés, William J. Sandborn, Séverine Vermeire, Silvio Danese, Brian G. Feagan, Jean‐Frédéric Colombel, Stephen B. Hanauer, Beth K. Rycroft - Clinical Gastroenterology and Hepatology 2015 cited by 446

  21. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

    Authors: William J. Sandborn, Brian G. Feagan, Douglas C. Wolf, Geert D’Haens, Séverine Vermeire, Stephen B. Hanauer, Subrata Ghosh, Heather Smith, Matthew Cravets, Paul Frohna, Richard Aranda, Sheila Gujrathi, Allan Olson - New England Journal of Medicine 2016 cited by 445

  22. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI Trial

    Authors: William J. Sandborn, Rory Rebuck, Yuhua Wang, Bin Zou, Omoniyi J. Adedokun, Christopher Gasink, Bruce E. Sands, Stephen B. Hanauer, Stephan R. Targan, Subrata Ghosh, Willem J.S. de Villiers, Jean‐Frédéric Colombel, Brian G. Feagan, John P. Lynch - Clinical Gastroenterology and Hepatology 2021 cited by 240

  23. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

    Authors: Walter Reinisch, William J. Sandborn, Daniël W. Hommes, G. D’Haens, Stephen B. Hanauer, Stefanie Schreiber, Remo Panaccione, Richard N. Fedorak, Mary Beth Tighe, Bidan Huang, Wendy Kampman, Andreas Lazar, Roopal Thakkar - Gut 2011 cited by 887

  24. A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis

    Authors: Geert D’Haens, William J. Sandborn, Brian G. Feagan, Karel Geboes, Stephen B. Hanauer, E. Jan Irvine, Marc Lémann, Philippe Marteau, Paul Rutgeerts, Jürgen Schölmerich, Lloyd R. Sutherland - Gastroenterology 2006 cited by 1,208